select a format

Single User License
USD 2000 INR 128580
Site License
USD 4000 INR 257160
Corporate User License
USD 6000 INR 385740

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Merkel Cell Carcinoma-Pipeline Review, H2 2016

Merkel Cell Carcinoma-Pipeline Review, H2 2016


  • Products Id :- GMDHC8896IDB
  • |
  • Pages: 157
  • |
  • December 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Merkel Cell Carcinoma-Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Merkel Cell Carcinoma-Pipeline Review, H2 2016, provides an overview of the Merkel Cell Carcinoma (Oncology) pipeline landscape.

Merkel cell carcinoma is a rare aggressive skin cancer that is at high risk of recurring and spreading (metastasizing) throughout the body. Risk factors for Merkel cell carcinoma include age, gender, light skin color, Ultraviolet exposure and immune suppression. Symptom includes painless nodule on skin. It usually starts on areas of skin exposed to the sun (face, neck, arms, and legs). Treatment includes chemotherapy, radiation therapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Merkel Cell Carcinoma-Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Merkel Cell Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Merkel Cell Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Merkel Cell Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 7, 5 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Merkel Cell Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Merkel Cell Carcinoma (Oncology).

The pipeline guide reviews pipeline therapeutics for Merkel Cell Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Merkel Cell Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Merkel Cell Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Merkel Cell Carcinoma (Oncology)

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Merkel Cell Carcinoma (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Merkel Cell Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Merkel Cell Carcinoma Overview 7

Pipeline Products for Merkel Cell Carcinoma-Overview 8

Pipeline Products for Merkel Cell Carcinoma-Comparative Analysis 9

Merkel Cell Carcinoma-Therapeutics under Development by Companies 10

Merkel Cell Carcinoma-Therapeutics under Investigation by Universities/Institutes 11

Merkel Cell Carcinoma-Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Merkel Cell Carcinoma-Products under Development by Companies 15

Merkel Cell Carcinoma-Products under Investigation by Universities/Institutes 16

Merkel Cell Carcinoma-Companies Involved in Therapeutics Development 17

Amgen Inc 17

Apcure SAS 18

BeiGene Ltd 19

Immune Design Corp 20

Merck & Co Inc 21

Merck KGaA 22

Millennium Pharmaceuticals Inc 23

NantKwest Inc 24

Novartis AG 25

OncoSec Medical Inc 26

Oncovir Inc 27

Ono Pharmaceutical Co Ltd 28

Merkel Cell Carcinoma-Therapeutics Assessment 29

Assessment by Monotherapy Products 29

Assessment by Target 30

Assessment by Mechanism of Action 32

Assessment by Route of Administration 34

Assessment by Molecule Type 36

Drug Profiles 38

aNK Program-Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

APC-001-Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

avelumab-Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

BGBA-317-Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

DNA IL-12-Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

EBC-46-Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

G-100-Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

nivolumab-Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

pasireotide-Drug Profile 91

Product Description 91

Mechanism Of Action 91

R&D Progress 91

pazopanib hydrochloride-Drug Profile 95

Product Description 95

Mechanism Of Action 95

R&D Progress 95

pembrolizumab-Drug Profile 102

Product Description 102

Mechanism Of Action 102

R&D Progress 102

Poly-ICLC-Drug Profile 139

Product Description 139

Mechanism Of Action 139

R&D Progress 139

sapanisertib-Drug Profile 142

Product Description 142

Mechanism Of Action 142

R&D Progress 142

talimogene laherparepvec-Drug Profile 145

Product Description 145

Mechanism Of Action 145

R&D Progress 145

Vaccine to Target WT1 for Oncology-Drug Profile 151

Product Description 151

Mechanism Of Action 151

R&D Progress 151

Merkel Cell Carcinoma-Product Development Milestones 152

Featured News & Press Releases 152

Nov 29, 2016: FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma for Priority Review 152

Nov 14, 2016: NantKwest Announces Achievement of End Point in Merkel Cell Carcinoma Phase II Trial With Evidence of Efficacy of Activated Natural Killer (aNK) Cells in Solid Tumors 153

Oct 31, 2016: European Medicines Agency Validates the Marketing Authorization Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma 153

Sep 28, 2016: Merck to Present Data on Avelumab at ESMO 2016 154

Appendix 156

Methodology 156

Coverage 156

Secondary Research 156

Primary Research 156

Expert Panel Validation 156

Contact Us 156

Disclaimer 157

List of Figures

Number of Products under Development for Merkel Cell Carcinoma, H2 2016 8

Number of Products under Development for Merkel Cell Carcinoma-Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 13

Assessment by Monotherapy Products, H2 2016 29

Number of Products by Top 10 Targets, H2 2016 30

Number of Products by Stage and Top 10 Targets, H2 2016 30

Number of Products by Top 10 Mechanism of Actions, H2 2016 32

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 32

Number of Products by Routes of Administration, H2 2016 34

Number of Products by Stage and Routes of Administration, H2 2016 34

Number of Products by Molecule Types, H2 2016 36

Number of Products by Stage and Molecule Types, H2 2016 36

List of Tables

Number of Products under Development for Merkel Cell Carcinoma, H2 2016 8

Number of Products under Development for Merkel Cell Carcinoma-Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Clinical Stage Development, H2 2016 13

Comparative Analysis by Early Stage Development, H2 2016 14

Products under Development by Companies, H2 2016 15

Products under Investigation by Universities/Institutes, H2 2016 16

Merkel Cell Carcinoma-Pipeline by Amgen Inc, H2 2016 17

Merkel Cell Carcinoma-Pipeline by Apcure SAS, H2 2016 18

Merkel Cell Carcinoma-Pipeline by BeiGene Ltd, H2 2016 19

Merkel Cell Carcinoma-Pipeline by Immune Design Corp, H2 2016 20

Merkel Cell Carcinoma-Pipeline by Merck & Co Inc, H2 2016 21

Merkel Cell Carcinoma-Pipeline by Merck KGaA, H2 2016 22

Merkel Cell Carcinoma-Pipeline by Millennium Pharmaceuticals Inc, H2 2016 23

Merkel Cell Carcinoma-Pipeline by NantKwest Inc, H2 2016 24

Merkel Cell Carcinoma-Pipeline by Novartis AG, H2 2016 25

Merkel Cell Carcinoma-Pipeline by OncoSec Medical Inc, H2 2016 26

Merkel Cell Carcinoma-Pipeline by Oncovir Inc, H2 2016 27

Merkel Cell Carcinoma-Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 28

Assessment by Monotherapy Products, H2 2016 29

Number of Products by Stage and Target, H2 2016 31

Number of Products by Stage and Mechanism of Action, H2 2016 33

Number of Products by Stage and Route of Administration, H2 2016 35

Number of Products by Stage and Molecule Type, H2 2016 37

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Amgen Inc, Apcure SAS, BeiGene Ltd, Immune Design Corp, Merck & Co Inc, Merck KGaA, Millennium Pharmaceuticals Inc, NantKwest Inc, Novartis AG, OncoSec Medical Inc, Oncovir Inc, Ono Pharmaceutical Co Ltd

Merkel Cell Carcinoma Therapeutic Products under Development, Key Players in Merkel Cell Carcinoma Therapeutics, Merkel Cell Carcinoma Pipeline Overview, Merkel Cell Carcinoma Pipeline, Merkel Cell Carcinoma Pipeline Assessment


Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com